The purpose of this study is to investigate the effect of multiple doses of carbamazepine on
two single doses of evobrutinib pharmacokinetics (PK) in healthy participants. Study details
include:
Study Duration: up to 54 days. Treatment Duration: 25 days. Visit Frequency: Participants
will be resident in the Clinical Research Unit from Day 1 to Day 20 and return on Day 26 for
a Safety Follow-Up visit.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany